TP04HN106
/ Talengen Institute of Life Sciences
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 02, 2025
A randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating the safety, efficacy, and pharmacokinetic profile of TP04HN106 treatment in patients with amyotrophic lateral sclerosis
(ChiCTR)
- P=N/A | N=60 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
New trial • Amyotrophic Lateral Sclerosis • CNS Disorders • Plasma NfL
1 to 1
Of
1
Go to page
1